Gadavist
Bayer’s Gadavist becomes first FDA-approved drug for MRI in coronary artery disease patients
July 16, 2019Manufacturing and Production, Sales and Marketing Bayer, FDA, Gadavist, coronary artery disease, pharma
The FDA has awarded approval to Bayer’s Gadavist (gadobutrol) injection, the company confirmed.
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
